SCHEMBL6320195

SCHEMBL6320195

CN[C@H](Cc1ccc2ccccc2c1)C(=O)N(C)[C@H](Cc1ccccc1)C(=O)NC[C@@H](C)O

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FCER2 P06734 3/20 0.46
MMP9 P14780 3/20 0.44
MMP8 P22894 3/20 0.44
PSMB1 P20618 1/20 0.44
PSMB5 P28074 1/20 0.44
PSMB2 P49721 1/20 0.44
F2 P00734 1/20 0.43
GHSR Q92847 2/20 0.43
MME P08473 4/20 0.43
ACE P12821 3/20 0.43
CPA1 P15085 2/20 0.43
ACE2 Q9BYF1 2/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8580483 1.00 FCER2 (0.46) FCER2MMP9MMP8PSMB1PSMB5
SCHEMBL6431509 1.00 FCER2 (0.46) FCER2MMP9MMP8PSMB1PSMB5
SCHEMBL6319850 0.91 MMP9 (0.42) FCER2MMP9MMP8PSMB1PSMB5
SCHEMBL6319261 0.90 MMP9 (0.42) FCER2MMP9MMP8PSMB1PSMB5
SCHEMBL8715806 0.89 FCER2 (0.52) FCER2MMP9MMP8PSMB1PSMB5
SCHEMBL6324655 0.89 MME (0.47) FCER2MMP9MMP8F2GHSR
SCHEMBL4427112 0.88 FCER2 (0.53) FCER2MMP9MMP8F2GHSR
SCHEMBL4426088 0.88 FCER2 (0.53) FCER2MMP9MMP8F2GHSR
SCHEMBL6317992 0.88 FCER2 (0.53) FCER2MMP9MMP8F2GHSR
SCHEMBL6320189 0.87 FCER2 (0.44) FCER2MMP9MMP8PSMB1PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 FCER2 4640/4885MMP9 2831/4885MMP8 4280/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR FCER2 4642/4885MMP9 3090/4885MMP8 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.